Ignacio
Gil Bazo
Ikertzailea 2022-(e)ra arte
Universidad Carlos III de Madrid
Madrid, EspañaUniversidad Carlos III de Madrid-ko ikertzaileekin lankidetzan egindako argitalpenak (2)
2023
-
Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients
Journal of Translational Medicine, Vol. 21, Núm. 1
2021
-
Delta-radiomics signature for prediction of survival in advanced nsclc patients treated with immunotherapy
Proceedings - International Symposium on Biomedical Imaging